C R Bard Inc (BCR) : Mckinley Carter Wealth Services reduced its stake in C R Bard Inc by 1.88% during the most recent quarter end. The investment management company now holds a total of 11,683 shares of C R Bard Inc which is valued at $2.6 Million after selling 224 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.C R Bard Inc makes up approximately 1.42% of Mckinley Carter Wealth Services’s portfolio.
Other Hedge Funds, Including , Autus Asset Management reduced its stake in BCR by selling 80 shares or 2.27% in the most recent quarter. The Hedge Fund company now holds 3,440 shares of BCR which is valued at $752,156. C R Bard Inc makes up approx 0.18% of Autus Asset Management’s portfolio.Cls Investments boosted its stake in BCR in the latest quarter, The investment management firm added 1,723 additional shares and now holds a total of 1,755 shares of C R Bard Inc which is valued at $383,731. C R Bard Inc makes up approx 0.02% of Cls Investments’s portfolio.Andra Ap-fonden reduced its stake in BCR by selling 7,100 shares or 8.95% in the most recent quarter. The Hedge Fund company now holds 72,200 shares of BCR which is valued at $15.6 Million. C R Bard Inc makes up approx 0.42% of Andra Ap-fonden’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in BCR by selling 210 shares or 1.27% in the most recent quarter. The Hedge Fund company now holds 16,308 shares of BCR which is valued at $3.5 Million. C R Bard Inc makes up approx 0.03% of Public Employees Retirement Association Of Colorado’s portfolio.
C R Bard Inc closed down -1.11 points or -0.50% at $220.17 with 5,15,160 shares getting traded on Wednesday. Post opening the session at $222.23, the shares hit an intraday low of $219.705 and an intraday high of $222.79 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Barclays on May 24, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 224 from a previous price target of $212 .Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.